Cybin Inc. (E:CYBN)
Business Focus: Bio Therapeutic Drugs
Cloudy as of March 01, 2023
For the latest outlook, get the company report
You may also be interested in
Insider Filings
Latest 10 SEDI filings for CYBN within the last 6 months
See all filings within the past 6 months
Read full article
Read full article
See more news stories
See all valuations
See Short Report
Loading...
Company News
Mar 08, 2023 07:30 ET
Cybin to Participate in the Oppenheimer 33rd Annual Healthcare Conference
Cybin Inc. (NEO:CYBN) (NYSE American:CYBN) (“Cybin” or the “Company”), a biopharmaceutical company focused on progressing Psychedelics to Therapeutics® is pleased to announce that Doug Drysdale, Cybin’s Chief Executive Officer, will participate in a virtual fireside chat at the Oppenheimer 33rd Annual Healthcare Conference taking pla
Mar 02, 2023 16:23 ET
Cybin and The Chopra Foundation to Participate in Featured Session at Upcoming 2023 South by Southwest® Conference
Cybin Inc. (NEO:CYBN) (NYSE American:CYBN) (“Cybin” or the “Company”), a biopharmaceutical company focused on progressing Psychedelics to Therapeutics® and The Chopra Foundation, a not-for-profit organization dedicated to improving health and well-being founded by Dr. Deepak Chopra, are pleased to announce that Dr. Chopra and Chief Execut
Valuation Ratios
Industry
Sector
Beta
N/A
--
--
Price to Sales - TTM
--
3.98
3.98
Price to Book - most recent quarter
1.73
1.59
1.68
Price to Cash Flow per share - TTM
--
3.32
10.03
Price to Free Cash Flow per share - TTM
--
3.72
15.26
Short Report
| Date | Number of Shares Shorted | Net Change |
|---|---|---|
| Mar 15, 2023 | 131,499 | 45,648 |
| Feb 28, 2023 | 85,851 | -73,792 |
| Feb 15, 2023 | 159,643 | 85,849 |
Business Summary
| Sector: Healthcare | Industry: Biotechnology & Medical Research |
Cybin Inc. is a Canada-based biotechnology company. The Company is focused on progressing Psychedelics to therapeutics by engineering drug discovery platforms, drug delivery systems, formulation approaches and treatment regimens for mental health disorders. Across the various research and development programs, the Company is researching and developing an array of synthetic psychedelic active pharmaceutical ingredients (API) intended to be delivered through drug delivery systems, including sublingual films1, orally disintegrating tablets (ODT)2, via inhalation and via intravenous (IV). Its drug programs include Depressive Disorder (CYB003), Alcohol Use Disorder (CYB003), Anxiety Disorders (CYB004) and Neuroinflammation (CYB005). The Company focuses on the clinical development path for CYB004, the Company's deuterated Phase 1 N,N-dimethyltryptamine (DMT) molecule, for the treatment of anxiety disorders. Its subsidiaries include Cybin Corp., Natures Journey Inc, and others.
See business summary
Disclaimer :: Use of this site is subject to, and your continued use
constitutes your express agreement to be bound by, our Legal and Terms of Use. Any commercial use of this site is
strictly prohibited. Canadianinsider.com is operated by INK Research Corp (INK). INK provides general information.
INK has made all reasonable efforts to ensure that all information provided is accurate at the time of inclusion;
however, there may be errors. INK makes no guarantee of accuracy or completeness. All information and opinion
expressed herein is subject to change without notice. Read more...Insider information is based on filings made on the System
for Electronic Disclosure for Insiders (SEDI®). Data is provided “as is” and by using this site
you acknowledge that the information which comprises the data is filed by or on behalf of the SEDI filers or other
parties legally required or permitted to do so. Filings may at any time contain errors and by using this site you
acknowledge this fact. INK is not an investment advisory service, a financial planner, an investment advisor nor a
securities advisor. INK does not purport to tell people, or suggest to people, what they should buy or sell for
themselves. Opinions and recommendations contained herein should not be construed as investment advice. Do not
assume that any recommendations, insights, charts, theories, or philosophies will ensure profitable investment.
Users should always consult with and obtain advice from their professional licensed financial advisor, including
their tax advisor, to determine the suitability of any investment. INK recommends that anyone making an investment
or trading securities do so with caution. Users should perform full due diligence and investigate any security
fully before making an investment or before the execution of a security trade based upon information learned
through INK. Investors should obtain annual reports and other company information to complete their own due
diligence in any investment. Neither INK nor anyone affiliated with INK is responsible for any investment decision
made. INK employees may have an ownership or investment interest in any stock mentioned in this service or on this
website. On this site, there may be third party content, content from authors or links to third-party sites or
pages, the contents of which are not verified, maintained, controlled or supervised by INK. INK is not responsible
for and assumes no liability for the accuracy, completeness or timeliness of any third party content or authored
content provided herein or the information or contents of any linked sites or pages. The inclusion of any authored
content or link by us does not imply that INK recommends, approves or endorses the authored content or linked site
or pages. INK Edge® and INK Research® are registered trade-marks owned by INK Research Corp. SEDI®
is a registered trade-mark owned by the Alberta Securities Commission.Read less
US Quotes Data provided by IEX. Additional price data powered by Twelve Data. Company fundamental sourced from © Refinitiv. Click for restrictions. © Refinitiv. All rights reserved. Republication or redistribution of Refinitiv, including by framing or similar means, is prohibited without the prior written consent of Refinitiv. Refinitiv is not liable for any errors or delays in Refinitiv content, or for any actions taken in reliance on such content.
Interactive technical study charts by TradingView. Copyright © 2023 INK Research Corp. All rights reserved. All trade-marks or trade names not owned by INK Research Corp. are the property of their respective owners.